Morphotek Inc., a subsidiary of Eisai Inc., entered into an agreement with the Targeted Alpha Therapy Group at the University of Gothenburg in Sweden to collaborate on the research and development of farletuzumab as an alpha therapy vector being studied for radioimmunotherapy in ovarian cancer.
The European Commission granted marketing authorization for Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
MD Anderson Cancer Center and Boehringer Ingelheim announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma.
FDA approved Ninlaro (ixazomib), developed by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is the first approved oral proteasome inhibitor.
Eli Lilly and Company and Merck extended an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s Alimta (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a phase III study in first-line nonsquamous non-small cell lung cancer. The study will be sponsored by Merck and will be open to patients with... […]
FDA approved Ninlaro (ixazomib), developed by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is the first approved oral proteasome inhibitor. The approval was based on an improvement... […]
FDA granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.
FDA approved Cotellic tablets (cobimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma.
FDA granted accelerated approval to Tagrisso (osimertinib) tablets for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy.
MD Anderson Cancer Center entered into a collaboration with CytomX Therapeutics to research Probody-enabled chimeric antigen receptor natural killer cell therapies, to be known as ProCAR-NK cell therapies. MD Anderson will develop allogeneic umbilical cord blood and peripheral blood derived NK-cell therapies and combine it with CytomX’s Probody technology to address new targets for this […]
